Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARTV Stock Forecast 2026-2027
$10.89
Current Price
$269.16M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ARTV Price Targets
+111.2%
To High Target of $23.00
+65.3%
To Median Target of $18.00
-8.2%
To Low Target of $10.00
ARTV Price Momentum
+0.8%
1 Week Change
+60.1%
1 Month Change
+423.6%
1 Year Change
+153.8%
Year-to-Date Change
-25.1%
From 52W High of $14.53
+640.8%
From 52W Low of $1.47
📊 TOP ANALYST CALLS
Did ARTV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Artiva is one of their latest high-conviction picks.
Latest ARTV Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ARTV has a bullish consensus with a median price target of $18.00 (ranging from $10.00 to $23.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $10.89, the median forecast implies a 65.3% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Martin Fan at Wedbush, projecting a 111.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARTV Analyst Ratings
6
Buy
0
Hold
0
Sell
ARTV Price Target Range
Low
$10.00
Average
$18.00
High
$23.00
Current: $10.89
Latest ARTV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARTV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 4, 2026 | Needham | Gil Blum | Buy | Reiterates | $18.00 |
| Mar 11, 2026 | Needham | Gil Blum | Buy | Reiterates | $18.00 |
| Nov 12, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $15.00 |
| Oct 17, 2025 | Needham | Gil Blum | Buy | Reiterates | $18.00 |
| Oct 17, 2025 | Wedbush | Martin Fan | Outperform | Maintains | $23.00 |
| Jun 11, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Assumes | $12.00 |
| May 15, 2025 | Needham | Gil Blum | Buy | Maintains | $18.00 |
| Apr 8, 2025 | Needham | Gil Blum | Buy | Reiterates | $23.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $20.00 |
| Mar 25, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Maintains | $20.00 |
| Mar 25, 2025 | Wedbush | Martin Fan | Outperform | Reiterates | $18.00 |
| Mar 25, 2025 | Needham | Gil Blum | Buy | Reiterates | $23.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Edward White | Buy | Initiates | $20.00 |
| Nov 13, 2024 | Needham | Gil Blum | Buy | Reiterates | $23.00 |
| Aug 30, 2024 | Needham | Gil Blum | Buy | Reiterates | $23.00 |
| Aug 13, 2024 | TD Cowen | Tyler Van Buren | Buy | Initiates | $N/A |
| Aug 13, 2024 | Wedbush | David Nierengarten | Outperform | Initiates | $18.00 |
| Aug 13, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $23.00 |
| Aug 13, 2024 | Needham | Gil Blum | Buy | Initiates | $23.00 |
| Aug 13, 2024 | Jefferies | Kelly Shi | Buy | Initiates | $21.00 |
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Competitors
The following stocks are similar to Artiva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Financial Data
Valuation Metrics
Market Cap
$269.16M
Enterprise Value
$209.17M
P/E Ratio
N/A
PEG Ratio
-5.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+40.1%
Current Ratio
8.6x
Debt/Equity
10.0x
ROE
-56.5%
ROA
-33.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Business Model
About Artiva Biotherapeutics, Inc. Common Stock
What They Do
Develops NK cell-based therapies for diseases.
Business Model
The company focuses on creating innovative therapies using natural killer (NK) cells, targeting autoimmune diseases and cancers. Its primary revenue generation strategy involves advancing clinical trials for its lead product, AlloNK, and other CAR-NK programs, which may lead to partnerships or eventual product sales upon regulatory approval.
Additional Information
Artiva Biotherapeutics, founded in 2019 and based in San Diego, California, emphasizes developing accessible cell therapies for serious medical conditions with high unmet needs. The company collaborates with strategic partners to enhance its NK cell manufacturing capabilities, supporting its therapeutic pipeline.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
104
CEO
Dr. Fred Aslan M.D.
Country
United States
IPO Year
2024
Website
www.artivabio.comArtiva Biotherapeutics, Inc. Common Stock (ARTV) Latest News & Analysis
Latest News
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
1 month ago
Quick Summary
Artiva Biotherapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 2:15 p.m. EDT. Audio webcast available on their website.
Why It Matters
Artiva Biotherapeutics' participation in a major healthcare conference signals its visibility in the biotech sector, potentially influencing stock interest and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
1 month ago
Quick Summary
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis is anticipated in the first half of 2026.
Why It Matters
The timeline for AlloNK® clinical data in refractory RA could influence market sentiment and stock performance for the company, impacting investment decisions in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
2 months ago
Quick Summary
Artiva Biotherapeutics appointed Thad Huston as CFO to enhance capital allocation and operational execution, supporting the advancement of AlloNK in autoimmune diseases.
Why It Matters
The appointment of a seasoned CFO like Thad Huston signals potential for improved financial management and strategic growth, which could enhance investor confidence and drive stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2 months ago
Quick Summary
Artiva Biotherapeutics (Nasdaq: ARTV) will participate in a fireside chat at the TD Cowen Health Care Conference on March 4, 2026, at 1:10 p.m. EST in Boston.
Why It Matters
Artiva Biotherapeutics' participation in a major healthcare conference highlights its visibility and potential for partnerships or funding, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Artiva Biotherapeutics appointed Elaine Sorg to its Board of Directors. She has over 35 years of experience in the biopharmaceutical industry, including in major immunology therapies.
Why It Matters
Elaine Sorg's appointment enhances Artiva's leadership, signaling potential for strategic growth and successful commercialization of its therapies, which may positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Artiva Biotherapeutics will present findings at the 2026 Tandem Meetings, showing that its AlloNK therapy is more cost-effective than CAR-T for rheumatologic diseases and durable for Non-Hodgkin Lymphoma.
Why It Matters
Artiva’s presentation on AlloNK's cost-effectiveness compared to CAR-T therapies could enhance its market position, attracting investor interest and potentially boosting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ARTV Stock
What is Artiva Biotherapeutics, Inc. Common Stock's (ARTV) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Artiva Biotherapeutics, Inc. Common Stock (ARTV) has a median price target of $18.00. The highest price target is $23.00 and the lowest is $10.00.
Is ARTV stock a good investment in 2026?
According to current analyst ratings, ARTV has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARTV stock?
Wall Street analysts predict ARTV stock could reach $18.00 in the next 12 months. This represents a 65.3% increase from the current price of $10.89. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Artiva Biotherapeutics, Inc. Common Stock's business model?
The company focuses on creating innovative therapies using natural killer (NK) cells, targeting autoimmune diseases and cancers. Its primary revenue generation strategy involves advancing clinical trials for its lead product, AlloNK, and other CAR-NK programs, which may lead to partnerships or eventual product sales upon regulatory approval.
What is the highest forecasted price for ARTV Artiva Biotherapeutics, Inc. Common Stock?
The highest price target for ARTV is $23.00 from Martin Fan at Wedbush, which represents a 111.2% increase from the current price of $10.89.
What is the lowest forecasted price for ARTV Artiva Biotherapeutics, Inc. Common Stock?
The lowest price target for ARTV is $10.00 from at , which represents a -8.2% decrease from the current price of $10.89.
What is the overall ARTV consensus from analysts for Artiva Biotherapeutics, Inc. Common Stock?
The overall analyst consensus for ARTV is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are ARTV stock price projections?
Stock price projections, including those for Artiva Biotherapeutics, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 3:17 AM UTC